Publicaciones en las que colabora con Féderico A. García (18)

2023

  1. Detection of High Level of Co-Infection and the Emergence of Novel SARS CoV-2 Delta-Omicron and Omicron-Omicron Recombinants in the Epidemiological Surveillance of Andalusia

    International journal of molecular sciences, Vol. 24, Núm. 3

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

2021

  1. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  2. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  3. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Current position of viral load versus hepatitis C core antigen testing

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, pp. 12-18

  2. Sample pooling for SARS-CoV-2 RT-PCR screening

    Clinical Microbiology and Infection, Vol. 26, Núm. 12, pp. 1687.e1-1687.e5

  3. The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain

    Scientific Reports, Vol. 10, Núm. 1

  4. Towards the elimination of hepatitis C: Implementation of reflex testing in Andalusia

    Revista Espanola de Enfermedades Digestivas, Vol. 112, Núm. 7, pp. 515-519

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  3. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy

    Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51

  4. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641

2018

  1. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals

    Diagnostic Microbiology and Infectious Disease, Vol. 89, Núm. 1, pp. 29-34

  3. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study)

    Journal of Viral Hepatitis, Vol. 24, Núm. 9, pp. 725-732

2014

  1. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194